Evidence map›Paper›PMID 29016845›Full record

ReviewNeuro-oncology2018

Pediatric low-grade gliomas: next biologically driven steps.

David T W Jones, Mark W Kieran, Eric Bouffet, Sanda Alexandrescu, Pratiti Bandopadhayay, Miriam Bornhorst, David Ellison, Jason Fangusaro, Michael J Fisher, Nicholas Foreman and 19 more

Erratum issued Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05555550 (Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas), which is not on this map. Cited by 101 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05555550 early_phase1recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)

TypeinterventionalSponsorChildren's Hospital of PhiladelphiaRan2026 to 2027Enrolled30ConditionsGlioma, Low-grade Glioma, Low Grade Glioma of Brain, Glioma, MalignantArms18F-Fluciclovine
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Molecular subtype prediction model for pediatric low-grade gliomas using conventional neuroradiology reporting.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

David T W JonesDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Hopp Children's Cancer Center, Heidelberg, Germany.
Mark W KieranDepartment of Medical Oncology, Brigham and Women's Hospital, Harvard Medical School, and the Broad Institutem, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
Eric BouffetPaediatric Neuro-Oncology Program, Research Institute, The Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Sanda AlexandrescuDepartment of Pathology, Harvard Medical School, Boston Children's Hospital, Boston, Massachusetts, USA.
Pratiti BandopadhayayDepartment of Medical Oncology, Brigham and Women's Hospital, Harvard Medical School, and the Broad Institutem, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
Miriam BornhorstGilbert Family Neurofibromatosis Institute, Brain Tumor Institute, Children's National Health System, Washington DC, USA.
David EllisonDepartment of Pathology and Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Jason FangusaroAnn and Robert H. Lurie Children's Hospital of Chicago Department of Pediatric Hematology/Oncology and Stem Cell Transplantation, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.
Michael J FisherDepartment of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Nicholas ForemanChildren's Hospital Colorado, University of Colorado, Aurora, Colorado, USA.
Maryam FouladiBrain Tumor Center, Brain Tumor Translational Research and Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.
Darren HargraveNeuro-oncology and Experimental Therapeutics, Great Ormond Street Hospital for Children, London, UK.
Cynthia HawkinsDivision of Pathology, The Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Nada JabadoDepartment of Pediatrics, McGill University, Montreal, Quebec, Canada.
Maura MassiminoPediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Sabine MuellerDepartment of Neurology, Pediatrics, and Neurosurgery, University of California San Francisco, San Francisco, California, USA.
Giorgio PerilongoDepartment of Woman's and Child's Health, University of Padua, Padua, Italy.
Antoinette Y N Schouten van MeeterenEmma Children's Hospital AMC, Amsterdam-Zuidoost, Netherlands.
Uri TaboriPaediatric Neuro-Oncology Program, Research Institute, The Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Katherine WarrenDepartment of Medical Oncology, Brigham and Women's Hospital, Harvard Medical School, and the Broad Institutem, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
Angela J WaandersDepartment of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
David WalkerChildren's Brain Tumor Research Centre, QMC University of Nottingham, Nottingham, UK.
William WeissDepartment of Neurology, Pediatrics, and Neurosurgery, University of California San Francisco, San Francisco, California, USA.
Olaf WittDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Hopp Children's Cancer Center, Heidelberg, Germany.
Karen Wright
Yuan ZhuGilbert Family Neurofibromatosis Institute, Brain Tumor Institute, Children's National Health System, Washington DC, USA.
Daniel C BowersDepartment of Pediatrics, UT Southwestern Medical School, Dallas, Texas, USA.
Stefan M PfisterDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Hopp Children's Cancer Center, Heidelberg, Germany.
Roger J PackerGilbert Family Neurofibromatosis Institute, Brain Tumor Institute, Children's National Health System, Washington DC, USA.

Funding

Research_ProjectU54HD090257 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI VITTORIO GALLO, VITTORIO GALLO VITTORIO GALLO · 2016 to 2020
$5.9M
Early Clinical Trials for Children with CNS TumorsZIABC011447 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WARREN, KATHERINE E · 2012 to 2019
$2.1M
NICHD NIH HHS U54 HD090257
6 · The paper itself

Abstract

Despite the fact that they are not typically life-threatening, low-grade gliomas (LGGs) remain a significant clinical challenge in pediatric neuro-oncology due to comorbidities associated with these tumors and/or their treatments, and their propensity to multiply recurs. LGGs, in total the most common brain tumors arising in childhood, can often become a chronic problem requiring decades of management. The Second International Consensus Conference on Pediatric Low-Grade Gliomas held in Padua, Italy in 2016 was convened in an attempt to advance the pace of translating biological discoveries on LGGs into meaningful clinical benefit. Topics discussed included: the implications of our growing biological understanding of the genomics underlying these tumors; the assessment of the model systems available; the implications of the molecular and histopathologic differences between adult and pediatric diffuse gliomas; and steps needed to expedite targeted therapy into late-stage clinical trials for newly diagnosed cases. Methods for the diagnostic assessment of alterations in the Ras/mitogen-activated protein kinase pathway, typical for these tumors, were also considered. While the overall tone was positive, with a consensus that progress is being and will continue to be made, the scale of the challenge presented by this complex group of tumors was also acknowledged. The conclusions and recommendations of the meeting panel are provided here as an outline of current thinking and a basis for further discussion.

Indexed as

Brain NeoplasmsGliomaPathology, MolecularAdultAnimalsChildDisease Models, AnimalHumansNeoplasm GradingTreatment Outcomelow-grade gliomaMAPK pathwaymolecular diagnosticsneurooncologypediatric brain tumortargeted therapy

Identifiers

PMID29016845
PMCPMC5786244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.